![]() |
|
|
Vol. 287, Issue 2, 441-447, November 1998
Department of Psychiatry (R.Y., T.T., K.A.) and
Department of
Pharmacology (N.Y., Y.U., Y.T., S.U., F.I.), University of Occupational
and Environmental Health, School of Medicine, Kitakyushu, Japan
Treatment of cultured bovine adrenal medullary cells with carbamazepine
(CBZ) for 5 days caused an increase in catecholamine secretion induced
by veratridine, an activator of voltage-dependent Na+
channels. However, no increase was stimulated by carbachol, an agonist
of nicotinic receptors, or by 56 mM K+, a depolarizing
agent that activates voltage-dependent Ca++ channels. CBZ
(30 µg/ml) treatment enhanced veratridine-induced catecholamine
secretion in a time-dependent manner (increases of 25%, 65% and 70%
for 3, 5 and 7 days of treatment, respectively). CBZ treatment (5 days)
increased veratridine-induced catecholamine secretion in a
concentration-dependent manner (increases of 27%, 36%, 45% and 55%
at 10, 15, 20 and 30 µg/ml of CBZ, respectively). CBZ treatment also
increased 22Na+ influx and
45Ca++ influx stimulated by veratridine. The
stimulatory effect of CBZ treatment on catecholamine secretion was
blocked by either actinomycin D or cycloheximide, an inhibitor of
protein synthesis. Additive responses of catecholamine secretion and
22Na+ influx induced by veratridine were
associated with combined exposure of the cells to CBZ and dibutyryl
cyclic AMP. CBZ treatment (30 µg/ml, 5 days) significantly increased
the specific binding of [3H]saxitoxin to cell membranes.
A Scatchard analysis of [3H]saxitoxin binding revealed
that CBZ increased the Bmax value without any
change in the dissociation constant. These findings suggest that CBZ
up-regulates the density and activity of voltage-dependent Na+ channels.
This article has been cited by other articles:
![]() |
K. Kajiwara, T. Yanagita, Y. Nakashima, A. Wada, F. Izumi, and N. Yanagihara Differential Effects of Short and Prolonged Exposure to Carvedilol on Voltage-Dependent Na+ Channels in Cultured Bovine Adrenal Medullary Cells J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 212 - 218. [Abstract] [Full Text] [PDF] |
||||